Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of alzheimer disease

mAbs

Volumn 5, Issue 5, 2013, Pages 665-864

  Giménez Llort, Lydia ^a,b   Rivera Hernández, Geovanny ^b   Marin Argany, Marta ^b   Sánchez Quesada, José L ^c   Villegas, Sandra ^b  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

Alzheimer disease; Amyloid oligomers; ApoE; ApoJ; Behavior; Clusterin; Immunotherapy; ScFv

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CLUSTERIN; SCFV H3D6; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; HIPPOCAMPUS; LEARNING DISORDER; LOCOMOTION; MOUSE; NONHUMAN; OLFACTORY BULB;

ALZHEIMER DISEASE; AMYLOID Β OLIGOMERS; APOE; APOJ; BEHAVIOR; CLUSTERIN; IMMUNOTHERAPY; SCFV;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; CEREBRAL CORTEX; CLUSTERIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOBLOTTING; LEARNING; MEMORY; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; OLFACTORY BULB; PRESENILIN-1; SINGLE-CHAIN ANTIBODIES; SWIMMING; TAU PROTEINS; TIME FACTORS;

EID: 84883875687     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25424     Document Type: Article

References (52)

1. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, et al. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 2012; 4:213-38; PMID:22339463; http://dx.doi.org/10.2217/imt.11.170
2. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3:824-8; PMID:12360327; http://dx.doi.org/10.1038/nrn938
3. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448-52; PMID:12640446; http://dx.doi.org/10.1038/nm840
4. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, et al. Antibodies against betaamyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-54; PMID:12765607; http://dx.doi.org/10.1016/S0896-6273(03)00294-0
5. Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, et al. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res 2011; 8:808-17; PMID:21592055; http://dx.doi.org/10.2174/156720511798192718
6. Thomas K. Trials for Alzheimer's drug halted after poor results. The New York Times 2012.
7. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, et al. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 2009; 30:364-76; PMID:17686552; http://dx.doi. org/10.1016/j.neurobiolaging.2007.06.013
8. Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010; 24:1281-93; PMID:20595065; http://dx.doi.org/10.1016/j.bbi.2010.05.010
9. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2011; 6:e18296; PMID:21483675; http://dx.doi. org/10.1371/journal.pone.0018296
10. Jacobson JS. Antibodies specific for epitopes within amyloid β (Aβ), for use in improving cognition. PCT Int Appl (2006), WO 2006066171 A1 20060622.
11. Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008; 7:805-11; PMID:18667360; http://dx.doi. org/10.1016/S1474-4422(08)70170-4
12. Marín-Argany M, Rivera-Hernández G, Martí J, Villegas S. An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway. Biochem J 2011; 437:25-34; PMID:21501114; http://dx.doi.org/10.1042/BJ20101712
13. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007; 282:23818-28; PMID:17548355; http://dx.doi.org/10.1074/jbc.M701078200
14. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101:1172-84; PMID:17286590; http://dx.doi.org/10.1111/j.1471- 4159.2006.04426.x
15. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39:409-21; PMID:12895417; http://dx.doi. org/10.1016/S0896-6273(03)00434-3
16. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, et al. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis 2007; 28:76-82; PMID:17659878; http://dx.doi.org/10.1016/j. nbd.2007.06.013
17. Mastrangelo MA, Bowers WJ. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci 2008; 9:81; PMID:18700006; http://dx.doi.org/10.1186/1471-2202-9-81
18. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45:675-88; PMID:15748844; http://dx.doi.org/10. 1016/j.neuron. 2005.01.040
19. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007; 31:125-47; PMID:17055579; http://dx.doi. org/10.1016/j.neubiorev. 2006.07.007
20. Giménez-Llort L, García Y, Buccieri K, Revilla S, Suñol C, Cristofol R, et al. Gender-specific neuroimmunoendocrine response to treadmill exercise in 3xTg-AD mice. Int J Alzheimers Dis 2010; 2010:128354; PMID:20981262; http://dx.doi. org/10.4061/2010/128354
21. García-Mesa Y, López-Ramos JC, Giménez-Llort L, Revilla S, Guerra R, Gruart A, et al. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J Alzheimers Dis 2011; 24:421-54; PMID:21297257
22. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352-7; PMID:16541076; http://dx.doi.org/10.1038/nature04533
23. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One 2008; 3:e2124; PMID:18461171; http://dx.doi.org/10.1371/journal.pone.0002124
24. España J, Giménez-Llort L, Valero J, Miñano A, Rábano A, Rodriguez-Alvarez J, et al. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 2010; 67:513-21; PMID:19664757; http://dx.doi.org/10.1016/j.biopsych.2009.06.015
25. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 2000; 50:305-15; PMID:10936885; http://dx.doi.org/10.1002/1097-0029(20000815)50: 4<305::AID-JEMT10>3.0.CO;2- L
26. Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA, et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide. Nat Struct Mol Biol 2012; 19:79-83; PMID:22179788; http://dx.doi. org/10.1038/nsmb.2191
27. Giménez-Llort L, Blázquez G, Cañete T, Rosa R, Vivó M, Oddo S, et al. Modeling neuropsychiatric symptoms of Alzheimer's disease dementia in 3xTg-AD mice. In: Alzheimer's Disease: New Advances. Iqbal K, Winblad B, Avila J, eds. Pianoro (BO), Italy: Medimond SRL, eds., 2006:513-516.
28. Ratia M, Giménez-Llort L, Camps P, Muñoz-Torrero D, Clos MV, Badia A. Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice. Pharmacol Biochem Behav 2010; 95:485-93; PMID:20363245; http://dx.doi.org/10.1016/j. pbb.2010.03.013
29. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11:47-60; PMID:6471907; http://dx.doi.org/10.1016/0165-0270(84)90007-4
30. Klein WL. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 2013; 33(Suppl 1):S49-65; PMID:22785404
31. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46:860-6; PMID:10589538; http://dx.doi.org/10.1002/1531-8249(199912)46:6<860::AID- ANA8>3.0.CO;2-M
32. Hedberg MM, Clos MV, Ratia M, Gonzalez D, Lithner CU, Camps P, et al. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice. Neurodegener Dis 2010; 7:379-88; PMID:20689242; http://dx.doi. org/10.1159/000287954
33. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, et al. Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci 2011; 31:7691-9; PMID:21613482; http://dx.doi. org/10.1523/JNEUROSCI.6637-10.2011
34. Gouras GK, Willén K, Tampellini D. Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ. Life Sci 2012; 91:1153-8; PMID:22727791; http://dx.doi. org/10.1016/j.lfs.2012.06.004
35. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8:499-509; PMID:17551515; http://dx.doi. org/10.1038/nrn2168
36. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43:321-32; PMID:15294141; http://dx.doi.org/10.1016/j.neuron. 2004.07.003
37. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, et al. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosisbeta or neurofibrillary degeneration. Acta Neuropathol 2007; 113:389-402; PMID:17237937; http://dx.doi. org/10.1007/s00401-006-0191-4
38. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003; 24:1063-70; PMID:14643377; http://dx.doi.org/10.1016/j. neurobiolaging.2003.08.012
39. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007; 21:2312-22; PMID:17412999; http://dx.doi. org/10.1096/fj.06-7986com
40. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999; 274:6875-81; PMID:10066740; http://dx.doi. org/10.1074/jbc.274.11. 6875
41. Hammad SM, Ranganathan S, Loukinova E, Twal WO, Argraves WS. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 1997; 272:18644-9; PMID:9228033; http://dx.doi.org/10.1074/jbc.272.30.18644
42. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61:89-104; PMID:19651157; http://dx.doi.org/10.1016/j.brainresrev.2009.05.007
43. Mahon MG, Lindstedt KA, Hermann M, Nimpf J, Schneider WJ. Multiple involvement of clusterin in chicken ovarian follicle development. Binding to two oocyte-specific members of the low density lipoprotein receptor gene family. J Biol Chem 1999; 274:4036-44; PMID:9933595; http://dx.doi.org/10.1074/jbc.274.7. 4036
44. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004; 41:193-202; PMID:14741101; http://dx.doi.org/10.1016/S0896-6273(03)00850-X
45. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004; 10:719-26; PMID:15195085; http://dx.doi.org/10.1038/nm1058
46. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008; 118:4002-13; PMID:19033669; http://dx.doi. org/10.1172/JCI36663
47. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994; 269:23403-6; PMID:8089103
48. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 2012; 287:41774-86; PMID:23060451; http://dx.doi.org/10.1074/jbc. M112.407957
49. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci 2011; 31:18007-12; PMID:22159114; http://dx.doi.org/10.1523/JNEUROSCI.3773-11.2011
50. Rivera-Hernández G, Marín-Argany M, Blasco-Moreno B, Bonet J, Oliva B, Villegas S. Elongation of the C-terminal domain of an anti-amyloid b singlechain variable fragment increases its thermodynamic stability and decreases its aggregation tendency. MAbs 2013; 5:678-89.
51. Lang UE, Lang F, Richter K, Vallon V, Lipp HP, Schnermann J, et al. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Res 2003; 145:179-88; PMID:14529816; http://dx.doi.org/ 10.1016/S0166-4328(03)00108-6
52. Wiltfang J, Arold N, Neuhoff V. A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity. Electrophoresis 1991; 12:352-66; PMID:1718736; http://dx.doi. org/10.1002/elps.1150120507